Vanguard Group’s Lipella Pharmaceuticals LIPO Stock Holding History

Vanguard Group’s Portfolio LIPO Stock Details LIPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,315	Closed	-$16.3K	–	4312
2024 Q3	$16.3K	Hold	4,315	–	–	﹤0.01%	4312
2024 Q2	$15.5K	Hold	4,315	–	–	﹤0.01%	4374
2024 Q1	$23.6K	Hold	4,315	–	–	﹤0.01%	4380
2023 Q4	$35.2K	Hold	4,315	–	–	﹤0.01%	4395
2023 Q3	$51.8K	Hold	4,315	–	–	﹤0.01%	4410
2023 Q2	$73.9K	Sell	4,315 -319	-7%	-$4.98K	﹤0.01%	4415
2023 Q1	$72.3K	Buy	+4,634	New	+$90.6K	﹤0.01%	4431

Other funds holding LIPO

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group's LIPO Position: Q4 2024 in Review

Vanguard Group sold out of Lipella Pharmaceuticals (LIPO) in Q4 2024, closing a stake of 4,315 shares — an estimated $16.3K sold.

Vanguard Group first reported a position in LIPO in Q1 2023 and held it in 7 quarters. The position peaked at $73.9K in Q2 2023. 3 funds tracked by Wall St. Rank hold LIPO as of Q4 2024.

Vanguard Group reported no remaining Lipella Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Vanguard Group sold 4,315 Lipella Pharmaceuticals shares in Q4 2024, an estimated $16.3K.
Vanguard Group first reported a position in Lipella Pharmaceuticals in Q1 2023 and held it in 7 quarters.
Vanguard Group's Lipella Pharmaceuticals position peaked at $73.9K in Q2 2023.
3 funds tracked by Wall St. Rank held Lipella Pharmaceuticals as of Q4 2024.

Based on Vanguard Group's 13F filing for Q4 2024, filed 11 Feb 2025.